Maintenance antipsychotic therapy: is the cure worse than the disease?
The serious long-term complications of maintenance antipsychotic therapy led the authors to undertake a critical review of outpatient withdrawal studies. Key findings included the following: 1) for a least 40% of outpatient schizophrenics, drugs seem to be essential for survival in the community; 2) the majority of patients who relapse after drug withdrawal recompensate fairly rapidly upon reinstitution of antipsychotic drug therapy; 3) placebo survivors seem to function as well as drug survivors--thus the benefit of maintenance drug therapy appears to be prevention of relapse; and 4) some cases of early relapse after drug withdrawal may be due to dyskinesia rather than psychotic decompensation. The authors urge clinicians to evaluate each patient on maintenance antipsychotic therapy in terms of feasibility of drug withdrawal and offer practical guidelines for withdrawal and subsequent management.
D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002746:Chlorpromazine / Q000008:administration & dosage; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D009069:Movement Disorders / Q000139:chemically induced; D011395:Promazine / Q000008:administration & dosage; D012008:Recurrence; D012559:Schizophrenia / Q000188:drug therapy*; D014268:Trifluoperazine / Q000008:administration & dosage
D014150:Antipsychotic Agents; D014268:Trifluoperazine; D011395:Promazine; D002746:Chlorpromazine